The Effects of Selective Serotonin Reuptake Inhibitors and Their Metabolites on S-mephenytoin 4'-hydroxylase Activity in Human Liver Microsomes

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1995 Nov 1

PMID 8703653

Citations 15

Authors

K Kobayashi

T Yamamoto

K Chiba

M Tani

T Ishizaki

Y Kuroiwa

Affiliations

Soon will be listed here.

Abstract

The inhibitory effects of four selective serotonin reuptake inhibitors (SSRIs), fluoxetine, sertraline, paroxetine and citalopram, and three metabolites (norfluoxetine, demethylcitalopram and didemethylcitalopram), on S-mephenytoin 4'-hydroxylation activities in human liver microsomes were studied. The 4'-hydroxylation of S-mephenytoin, a representative substrate toward CYP2C19, was competitively inhibited by all the SSRIs and their metabolites studied. The mean Ki values of fluoxetine, norfluoxetine, sertraline, paroxetine, citalopram, demethylcitalopram and didemethylcitalopram were 5.2, 1.1, 2.0, 7.5, 87.3, 55.8 and 7.7 microM, respectively. The findings suggest that some SSRIs and their metabolites with a low Ki value (e.g., fluoxetine, norfluoxetine) may reduce the clearance of drugs metabolized by this isoform of P450, thereby resulting in a possible drug-drug interaction, when administered simultaneously. In addition, SSRIs and their metabolites examined herein may be substrates toward CYP2C19.

Citing Articles

PharmGKB summary: sertraline pathway, pharmacokinetics.

Huddart R, Hicks J, Ramsey L, Strawn J, Smith D, Babilonia M Pharmacogenet Genomics. 2019; 30(2):26-33.

PMID: 31851125 PMC: 7008964. DOI: 10.1097/FPC.0000000000000392.

Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.

Khojasteh S, Prabhu S, Kenny J, Halladay J, Lu A Eur J Drug Metab Pharmacokinet. 2011; 36(1):1-16.

PMID: 21336516 DOI: 10.1007/s13318-011-0024-2.

Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Yeung C, Fujioka Y, Hachad H, Levy R, Isoherranen N Clin Pharmacol Ther. 2010; 89(1):105-13.

PMID: 21124313 PMC: 3474849. DOI: 10.1038/clpt.2010.252.

A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer.

Isomura Y, Yamaji Y, Ohta M, Seto M, Asaoka Y, Tanaka Y J Gastroenterol. 2010; 45(10):1045-52.

PMID: 20549256 DOI: 10.1007/s00535-010-0246-0.

The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

VandenBrink B, Isoherranen N Curr Opin Drug Discov Devel. 2010; 13(1):66-77.

PMID: 20047147 PMC: 2898504.

References

Eichelbaum M, Spannbrucker N, Steincke B, DENGLER H . Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979; 16(3):183-7. DOI: 10.1007/BF00562059. View

Yasumori T, Li Q, Yamazoe Y, Ueda M, Tsuzuki T, Kato R . Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation. Pharmacogenetics. 1994; 4(6):323-31. DOI: 10.1097/00008571-199412000-00005. View

Mellstrom B, Bertilsson L, Sawe J, Schulz H, Sjoqvist F . E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther. 1981; 30(2):189-93. DOI: 10.1038/clpt.1981.147. View

Bertilsson L, Aberg-Wistedt A . The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol. 1983; 15(3):388-90. PMC: 1427780. DOI: 10.1111/j.1365-2125.1983.tb01518.x. View

Oyehaug E, Ostensen E, Salvesen B . High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr. 1984; 308:199-208. View

Inaba T, Jurima M, Mahon W, KALOW W . In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos. 1985; 13(4):443-8. View

Gugler R, Jensen J . Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology. 1985; 89(6):1235-41. View

Brosen K, Klysner R, Gram L, Otton S, Bech P, Bertilsson L . Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol. 1986; 30(6):679-84. DOI: 10.1007/BF00608215. View

Benfield P, Heel R, Lewis S . Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986; 32(6):481-508. DOI: 10.2165/00003495-198632060-00002. View

10.

Hall S, Guengerich F, Branch R, Wilkinson G . Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther. 1987; 240(1):216-22. View

11.

Lemberger L, Rowe H, Bosomworth J, Tenbarge J, Bergstrom R . The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther. 1988; 43(4):412-9. DOI: 10.1038/clpt.1988.52. View

12.

Bertilsson L, Henthorn T, Sanz E, Tybring G, Sawe J, Villen T . Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther. 1989; 45(4):348-55. DOI: 10.1038/clpt.1989.40. View

13.

Kaye C, Haddock R, LANGLEY P, Mellows G, Tasker T, Zussman B . A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl. 1989; 350:60-75. DOI: 10.1111/j.1600-0447.1989.tb07176.x. View

14.

Yasumori T, Murayama N, Yamazoe Y, Kato R . Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin Pharmacol Ther. 1990; 47(3):313-22. DOI: 10.1038/clpt.1990.34. View

15.

Skjelbo E, Brosen K, Hallas J, Gram L . The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther. 1991; 49(1):18-23. DOI: 10.1038/clpt.1991.4. View

16.

Brosen K, Gram L, Kragh-Sorensen P . Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit. 1991; 13(2):177-82. DOI: 10.1097/00007691-199103000-00015. View

17.

Milne R, Goa K . Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991; 41(3):450-77. DOI: 10.2165/00003495-199141030-00008. View

18.

Sindrup S, Brosen K, Gram L, Hallas J, Skjelbo E, Allen A . The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992; 51(3):278-87. DOI: 10.1038/clpt.1992.23. View

19.

Warrington S . Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol. 1991; 6 Suppl 2:11-21. DOI: 10.1097/00004850-199112002-00004. View

20.

Sohn D, Kusaka M, Ishizaki T, Shin S, Jang I, Shin J . Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther. 1992; 52(2):160-9. DOI: 10.1038/clpt.1992.125. View